| Glaucoma |
| | Optic
nerve health approach in glaucoma therapy
Chairperson: A.G.P. Konstas
|
| Neuroprotection
L. Levin |
| Clinical
implications of ocular blood flow
O. Arend |
| | IOP
J. Thygesen |
|
| The
present algorithm of glaucoma therapy
Moderator: J. P. Nordmann |
| The fight
for the declaration of THE first line drug and the algorithm that follows
N. Pfeiffer |
| Confronting
the algorithms with specific patient cases
Panel discussion: J. Jonas,
A. Konstas |
| |
The positioning of the various structurally
related prostaglandin derived drugs
Moderator: P. Netland |
| Bimatoprost
(Lumigan)
J. Thygesen |
| Travoprost
(Travatan)
P. Netland |
| Unoprostone
( Rescula)
J.P. Nordmann |
| Latanoprost
(Xalatan)
R. Feldman |
| Discussion:
M. Teus, J.P. Nordmann, M. Vidal-Sanz |
| | Glaucoma
Drug Development |
| |
From the laboratory to the patient: finding the path
P. Kaufman
|
| Effects
on NO inhibitors on IOP
F. Drago |
| Retina |
| Prevention
of AMD
Chairperson: E. Friedman |
| Scleral
rigidity and AMD prevention: The AirBag concept
M.K. Tsilimbaris |
| Recent
nutritional, epidemiological, and genetic factors associated with AMD
J. Seddon |
| New
leads for possible pharmacological intervention
E. Friedman |
| Anti-angiogenesis
and AMD
Chairperson: B. Kuppermann |
|
| Rationale of anti-angiogenic therapy for
AMD.
B. Kuppermann |
| anti-VEGF
compounds: |
| |
The anti-VEGF aptamer
S. Patel |
|
| rhu-Fab anti VEGF
T. McCluskey |
| Steroids |
| Intravitreal
triamcinolone
R. Danis |
|
| Anecortave acetate
M.D.
de Smet |
| |
Steroid implants
B. Kuppermann |
|
Video
R. Danis |
| Adenoviral
PEDF
L. Wei |
| Q&A
|
| | Photodynamic
therapy
Chairperson: J. Monés |
|
| Current Trials on Visudyne
J. Monés |
| | Angiographic
features after photodynamic therapy
S. Michels |
|
| PDT and Angioid Streaks
U. Menchini |
| | Decision
making in PDT retreatments. Monitoring metamorphopsia
J. Monés |
| SnET2
Phase III-Failure to Reach Significance
E. L. Thomas |
| ICG
enhanced treatment for CNV
M. Ed Farah |
|
| Discussion |
|
| Diabetic Retinopathy
Chairperson: S. Bursell |
|
| Protein Kinase-C inhibitors: A
potential novel therapy for reducing the risks of diabetic retinopathy and macula
edema
S. Bursell |
| | Dexamethasone
implant for diabetic macular edema
B. Kuppermann |
|
| Cytokine network in angiogenesis
in diabetic retinopathy
H. Yamashita |
|
| Preventing
vitreoproliferative retinopathy
Chairperson: J.C. Pastor |
| | What
is PVR?
J.C. Pastor |
|
| Chronobiology of PVR
E. Rodriguez
de la Rua |
| |
Clinical risk factors for PVR
V. Martinez |
|
| Pharmacological prophylaxis
R. Asaria |
| |
Intravitreal injection of Trimacinolone acetonide
J. Jonas |
| | Development
of VitrenASE™
J.M. Robbins |
|
Inflammation & Infection
|
| Potent
anti-inflammatory agents for sight threatening inflammatory diseases with limited
supporting clinical studies
Chairperson: J. Rosenbaum |
| | The
problem (epidemiological data) and the diseases
S. Lightman |
| | Evidence
based medicine and use of medications
P. McCluskey |
| Treating
Uveitis 2002: Algorithms and management
Chairperson: S. Lightman |
| | The
place of novel biologic inflammatory modulators
J. Rosenbaum |
| Intraocular
delivery of anti-inflammatory drugs
H. Towler |
| | Interferon
|
| | Immunological
Effects of Interferon
G. Spagnoli |
| | Effects
of IFN in tumours
J. Böttjer |
| | IFN
in intraocular inflammation
M. Zierhut |
|
| Allergic
eye diseases
Chairperson: S. Bonini, R. Neumann |
| | New targets
for allergy molecular level overview
R. Eisenberg |
| | Understanding
the key role of T-cells in chronic allergic eye disease
V. Calder |
| | New
drugs for allergy (clinical experience)
- Mast cell
stabilizers - why do we miss the effect?
- Combined mast cell stabilizers
& anti-histamine: new content or new wrapping?
S. Bonini |
| | The
current algorithm of allergic eye conditions
R. Neumann |
Cornea
& ext. segment
Chairperson: P.
Asbell |
| |
Endpoints in dry eye clinical trials |
| | Signs not equal to symptoms - Introduction
P. A. Asbell |
| | The dry eye chamber
G. Ousler |
| | End
points in clinical trials
D. Kellerman |
| | Tear
proteins
C. Morris |
| | Corneal permeability
in dry eyes
P. A. Asbell |
| | Confocal studies
of dry eyes
R. Beuerman |
| | Panel: All speakers |
| |
New treatments for ocular surface pathology
|
| | Pathophysiology of dry eye
M. Stern |
| | New lacrimal plugs for dry eyes
C.J. Spaleck |
| | Mucin stimulators
P. A. Asbell |
| | Nutritional
treatments
S. Pratt |
| | PANEL: All speakers
and audience |
| |
Lasik
Chairperson: J. Alio |
| | Pathogenesis
of dry eye after Lasik
J. Alio |
|
| Immediate and late post surgical therapy
J. Montero |
| |
Pharmaceuticals after LASIK
J.J. Perez-Santonja |
| | How to prevent
ocular surface problem after LASIK
J. Merayo |
| Novel
approaches to understanding and treating ocular Infectious diseases: A primer
on microbial genomics and proteomics
Chairperson: T. O'Brien |
| The problems
in ocular infectious diseases
T. O'Brien |
| Proteomics
D. Garland |
| Genomics
D. Sinha |
| Clinical
relevance
T. O'Brien |
|
| Prevention
of cataract
Chairperson: |
|
| The role of vitamins/antioxidants
on prevention of cataracts vs. the dangers of hypervitaminosis - a dietary common
sense
S. Pratt |
|
| Dose-dependent prevention of sugar cataracts
in galactose-fed dogs by aldose reductase inhibitors; a model for humans?
P. Kador |
|
Anti Cancer
Chairperson:
J. Pe'er
Under
the auspices of
THE CLAIRE
AND AMEDEE MARATIER INSTITUTE FOR THE STUDY OF BLINDNESS & VISUAL DISORDERS |
| | The
use of cytotoxic drugs in the treatment of ocular surface malignancies
J. Frucht-Pery |
| |
The use of interferone alpha in the treatment of epithelial ocular surface malignancies
C. Karp |
| |
Experimental new methods of local chemotherapy in the treatment of intraocular
tumors
T. Murray |
| |
The use of intravitreal methotrexate in the treatment of intraocular lymphoma
J. Pe'er |
|
Drug delivery & Drug toxicity
|
| |
Drug delivery 1
Chairperson: R. Gurny
|
| |
Ocular iontophoresis
F. Behar-Cohen |
|
| Intraocular delivery with polymeric devices
S. Einmahl |
| |
Challenges associated with topical delivery
O. Felt |
| |
Drug delivery 2
Chairperson: P. Ashton |
| | Introduction
P. Ashton |
| |
Development of Surodex a bioerodible system for delivery to the anterior chamber
|
| |
Delivery of therapeutic biological compounds to the eye via the trans-scleral
route
J. Ambati |
|
| Drugs
toxicity
Chairperson: F. Fraunfelder |
|
| Global legal obligations for pharmacovigilance
in the industry.
M. Fsadni |
|
| The latest methods of pharmacovigilance for
ophthalmology
R. Fraunfelder |
|
| Which drugs are causing the greatest interest
as to visual side-effects today?
F. Fraunfelder |
| Basic
Science Sessions |
| |
Antioxidants
Chairperson: T. Hiramitsu,
T. Nakanishi-Ueda |
|
| Antioxidant effect of a novel free radical
scanveger, edaravone (Radicut), on retinal oxidative stress
T. Hiramitsu
|
| |
Protective effect of phenyl-N-tert-butylnitrone (PBN) against retinal light damage
I. Ranchon |
| |
Evidence for an antioxidant function of lutein and zeaxanthin in human retina.
LM. Rapp |
| |
Intracellular signaling pathways and trafficking as potential targets for drug
intervention
Chairperson: C. Paterson |
|
| Neurotrophic factor signalling in retinal
photoreceptors
D. Hicks |
|
| Glucocorticoids directly increase retinal
endothelial cell barrier properties by regulating tight junctions
D.
Antonetti |
| |
Insulin signalling in retinal neurones
T. Gardner |
| | A stress
response specific for the eye's aqueous outflow pathways is diagnostic of glaucoma
E. Fini |
| |
Antiangiogenesis
Chairperson: A. Das |
|
| Ocular Antiangiogenesis: Pathophysiology and
strategies for inhibition
A. Das |
|
| Use of Somatostatin analogs in inhibition
of retinal angiogenesis
S. Caballero |
|
| Retinal angiogenesis: Role of nitric oxide
synthase
R. Caldwell |
|
| Use of proteinase inhibitors in retinal angiogenesis
A. Das |
| |
Gene therapy approaches in the treatment of intraocular neovascularization
D. Hinton |
| |
Gene therapy
Chairperson: W. Stewart
|
| |
Glaucoma genetics: Basic science
E. Si |
|
| Glaucoma genetics, clinical applications:
ISV-205
W. Stewart |
|
| Dual effect of of APOE promoter SNPs on phenotype
of primary open-angle glaucoma and interaction with the MYOCILIN gene
H-J. Garchon |
| |
Towards molecular identification and characterization of an adult-onset primary
open angle glaucoma gene
M. Sarfarazi |
|
| Apoptosis
Chairperson: N. Agarwal |
|
| Gene therapy for retinal degnerative diseases
M. M. La Vail |
| |
Is endothelin a contributor in glaucoma?
G. Prasanna |
| | Apoptosis
and neuroprotection of retinal ganglion cells in glaucoma
N. Agarwal
|
| |
Neuroprotection
Discussion panel
Moderator:
L. Levin,
Panel: D. Gil , E. Wong, W. Chambers |
| | What pharmacological
strategies are least/most likely to succeed? |
|
| What animal models are most valuable? |
| | What kinds
of trials are necessary for testing neuroprotection in clinical disease? |
| | What outcome
measures are most useful? |
|
Imaging |
| |
Imaging 1
Chairperson: N. Lois |
| | Development
of new methodologies for multimodal macular mapping
R. Bernardes
|
| |
Fundus autofluorescence using a confocal SLO
N. Lois |
| | Vitreo-retinal
interface by OCT
T. Williamson |
|
| Future 3D SLO-OCT applications
F.D. Verbraak |
| |
Imaging 2
Chairperson: S. Krupsky |
| | Imaging
of the optic nerve
J. Jonas |
|
| Can optic nerve hemodynamic changes predict
progression of glaucoma?
J Grunwald |
|
| Panel: Imaging as a tool in drug development
|
